Rare Diseases Are Not Rare in China: What can be done more for this Special Category of Patients (CEIBS Working Paper, No. 046/2022/MKT/POM, 2022)

Eric Bouteiller

Rare Diseases Are Not Rare in China: What can be done more for this Special Category of Patients (CEIBS Working Paper, No. 046/2022/MKT/POM, 2022)

Research output: Working paper

261 Downloads (Pure)

Abstract

During the 2022 session of “two meetings”, rare diseases have been cited as one of the focus in healthcare in Prime Minister working report2. It is an important recognition of the severity of the issue and the need to find practical solutions. This article summarizes the situation of drugs against rare diseases in China and the progress already done. Moving forward, it suggests upgrading their positioning in the healthcare strategy in order to solve an important social issue and bring more steam into innovation in pharmaceutical.

Original language	English
Publication status	Published - Mar 2022

Source

China Europe International Business School (CEIBS)

Keywords

healthcare
health

Access to Document

046-Bouteiller, Eric_Mar 2022_0Final published version, 318 KBLicence: CC BY-NC-ND

https://www.ceibs.edu/sites/portal.prod.dpmgr.ceibs.edu/files/2023-02/046-Bouteiller%2C%20Eric_Mar%202022_0.pdfLicence: CC BY-NC-ND

OpenUrl availability

Full text

Cite this

@techreport{78810797933e4b3d8505a819c170af87,

title = "Rare Diseases Are Not Rare in China: What can be done more for this Special Category of Patients (CEIBS Working Paper, No. 046/2022/MKT/POM, 2022)",

abstract = "During the 2022 session of “two meetings”, rare diseases have been cited as one of the focus in healthcare in Prime Minister working report2. It is an important recognition of the severity of the issue and the need to find practical solutions. This article summarizes the situation of drugs against rare diseases in China and the progress already done. Moving forward, it suggests upgrading their positioning in the healthcare strategy in order to solve an important social issue and bring more steam into innovation in pharmaceutical.",

keywords = "healthcare, health",

author = "Eric Bouteiller",

year = "2022",

month = mar,

language = "English",

type = "WorkingPaper",

}

TY - UNPB

T1 - Rare Diseases Are Not Rare in China

T2 - What can be done more for this Special Category of Patients (CEIBS Working Paper, No. 046/2022/MKT/POM, 2022)

AU - Bouteiller, Eric

PY - 2022/3

Y1 - 2022/3

N2 - During the 2022 session of “two meetings”, rare diseases have been cited as one of the focus in healthcare in Prime Minister working report2. It is an important recognition of the severity of the issue and the need to find practical solutions. This article summarizes the situation of drugs against rare diseases in China and the progress already done. Moving forward, it suggests upgrading their positioning in the healthcare strategy in order to solve an important social issue and bring more steam into innovation in pharmaceutical.

AB - During the 2022 session of “two meetings”, rare diseases have been cited as one of the focus in healthcare in Prime Minister working report2. It is an important recognition of the severity of the issue and the need to find practical solutions. This article summarizes the situation of drugs against rare diseases in China and the progress already done. Moving forward, it suggests upgrading their positioning in the healthcare strategy in order to solve an important social issue and bring more steam into innovation in pharmaceutical.

KW - healthcare

KW - health

M3 - Working paper

BT - Rare Diseases Are Not Rare in China

ER -

Rare Diseases Are Not Rare in China: What can be done more for this Special Category of Patients (CEIBS Working Paper, No. 046/2022/MKT/POM, 2022)

Abstract

Source

Keywords

Access to Document

OpenUrl availability

Fingerprint

Cite this